Scolaris Content Display Scolaris Content Display

Comparison 1 ASA or ASA/DIP vs nothing, all grafts, Outcome 1 Primary graft patency at 12 months.
Figures and Tables -
Analysis 1.1

Comparison 1 ASA or ASA/DIP vs nothing, all grafts, Outcome 1 Primary graft patency at 12 months.

Comparison 1 ASA or ASA/DIP vs nothing, all grafts, Outcome 2 Amputation rate.
Figures and Tables -
Analysis 1.2

Comparison 1 ASA or ASA/DIP vs nothing, all grafts, Outcome 2 Amputation rate.

Comparison 1 ASA or ASA/DIP vs nothing, all grafts, Outcome 3 Cardiovascular events.
Figures and Tables -
Analysis 1.3

Comparison 1 ASA or ASA/DIP vs nothing, all grafts, Outcome 3 Cardiovascular events.

Comparison 1 ASA or ASA/DIP vs nothing, all grafts, Outcome 4 Gastrointestinal side‐effects.
Figures and Tables -
Analysis 1.4

Comparison 1 ASA or ASA/DIP vs nothing, all grafts, Outcome 4 Gastrointestinal side‐effects.

Comparison 1 ASA or ASA/DIP vs nothing, all grafts, Outcome 5 Death.
Figures and Tables -
Analysis 1.5

Comparison 1 ASA or ASA/DIP vs nothing, all grafts, Outcome 5 Death.

Comparison 1 ASA or ASA/DIP vs nothing, all grafts, Outcome 6 Side effects.
Figures and Tables -
Analysis 1.6

Comparison 1 ASA or ASA/DIP vs nothing, all grafts, Outcome 6 Side effects.

Comparison 1 ASA or ASA/DIP vs nothing, all grafts, Outcome 7 Major Bleeding.
Figures and Tables -
Analysis 1.7

Comparison 1 ASA or ASA/DIP vs nothing, all grafts, Outcome 7 Major Bleeding.

Comparison 1 ASA or ASA/DIP vs nothing, all grafts, Outcome 8 Minor bleeding.
Figures and Tables -
Analysis 1.8

Comparison 1 ASA or ASA/DIP vs nothing, all grafts, Outcome 8 Minor bleeding.

Comparison 1 ASA or ASA/DIP vs nothing, all grafts, Outcome 9 Wound or graft infection.
Figures and Tables -
Analysis 1.9

Comparison 1 ASA or ASA/DIP vs nothing, all grafts, Outcome 9 Wound or graft infection.

Comparison 2 ASA or ASA/DIP vs nothing, subgroups, Outcome 1 Primary graft patency, venous grafts, 1 month.
Figures and Tables -
Analysis 2.1

Comparison 2 ASA or ASA/DIP vs nothing, subgroups, Outcome 1 Primary graft patency, venous grafts, 1 month.

Comparison 2 ASA or ASA/DIP vs nothing, subgroups, Outcome 2 Primary graft patency, venous grafts, 3 months.
Figures and Tables -
Analysis 2.2

Comparison 2 ASA or ASA/DIP vs nothing, subgroups, Outcome 2 Primary graft patency, venous grafts, 3 months.

Comparison 2 ASA or ASA/DIP vs nothing, subgroups, Outcome 3 Primary graft patency, venous grafts, 6 months.
Figures and Tables -
Analysis 2.3

Comparison 2 ASA or ASA/DIP vs nothing, subgroups, Outcome 3 Primary graft patency, venous grafts, 6 months.

Comparison 2 ASA or ASA/DIP vs nothing, subgroups, Outcome 4 Primary graft patency, venous grafts, 12 months.
Figures and Tables -
Analysis 2.4

Comparison 2 ASA or ASA/DIP vs nothing, subgroups, Outcome 4 Primary graft patency, venous grafts, 12 months.

Comparison 2 ASA or ASA/DIP vs nothing, subgroups, Outcome 5 Primary graft patency, venous grafts, 24 months.
Figures and Tables -
Analysis 2.5

Comparison 2 ASA or ASA/DIP vs nothing, subgroups, Outcome 5 Primary graft patency, venous grafts, 24 months.

Comparison 2 ASA or ASA/DIP vs nothing, subgroups, Outcome 6 Primary graft patency, prosthetic grafts, 1 month.
Figures and Tables -
Analysis 2.6

Comparison 2 ASA or ASA/DIP vs nothing, subgroups, Outcome 6 Primary graft patency, prosthetic grafts, 1 month.

Comparison 2 ASA or ASA/DIP vs nothing, subgroups, Outcome 7 Primary graft patency, prosthetic grafts, 3 months.
Figures and Tables -
Analysis 2.7

Comparison 2 ASA or ASA/DIP vs nothing, subgroups, Outcome 7 Primary graft patency, prosthetic grafts, 3 months.

Comparison 2 ASA or ASA/DIP vs nothing, subgroups, Outcome 8 Primary graft patency, prosthetic grafts, 6 months.
Figures and Tables -
Analysis 2.8

Comparison 2 ASA or ASA/DIP vs nothing, subgroups, Outcome 8 Primary graft patency, prosthetic grafts, 6 months.

Comparison 2 ASA or ASA/DIP vs nothing, subgroups, Outcome 9 Primary graft patency, prosthetic grafts, 12 months.
Figures and Tables -
Analysis 2.9

Comparison 2 ASA or ASA/DIP vs nothing, subgroups, Outcome 9 Primary graft patency, prosthetic grafts, 12 months.

Comparison 3 Aspirin or ASA/DIP versus pentoxifylline (PTX), all grafts, Outcome 1 Primary graft patency, 1 month.
Figures and Tables -
Analysis 3.1

Comparison 3 Aspirin or ASA/DIP versus pentoxifylline (PTX), all grafts, Outcome 1 Primary graft patency, 1 month.

Comparison 3 Aspirin or ASA/DIP versus pentoxifylline (PTX), all grafts, Outcome 2 Primary graft patency, 3 months.
Figures and Tables -
Analysis 3.2

Comparison 3 Aspirin or ASA/DIP versus pentoxifylline (PTX), all grafts, Outcome 2 Primary graft patency, 3 months.

Comparison 3 Aspirin or ASA/DIP versus pentoxifylline (PTX), all grafts, Outcome 3 Primary graft patency, 6 months.
Figures and Tables -
Analysis 3.3

Comparison 3 Aspirin or ASA/DIP versus pentoxifylline (PTX), all grafts, Outcome 3 Primary graft patency, 6 months.

Comparison 3 Aspirin or ASA/DIP versus pentoxifylline (PTX), all grafts, Outcome 4 Primary graft patency, 12 months.
Figures and Tables -
Analysis 3.4

Comparison 3 Aspirin or ASA/DIP versus pentoxifylline (PTX), all grafts, Outcome 4 Primary graft patency, 12 months.

Comparison 4 ASA/DIP versus indobufen, prosthetic grafts, Outcome 1 Primary graft patency, 3 months.
Figures and Tables -
Analysis 4.1

Comparison 4 ASA/DIP versus indobufen, prosthetic grafts, Outcome 1 Primary graft patency, 3 months.

Comparison 4 ASA/DIP versus indobufen, prosthetic grafts, Outcome 2 Primary graft patency, 6 months.
Figures and Tables -
Analysis 4.2

Comparison 4 ASA/DIP versus indobufen, prosthetic grafts, Outcome 2 Primary graft patency, 6 months.

Comparison 4 ASA/DIP versus indobufen, prosthetic grafts, Outcome 3 Primary graft patency, 9 months.
Figures and Tables -
Analysis 4.3

Comparison 4 ASA/DIP versus indobufen, prosthetic grafts, Outcome 3 Primary graft patency, 9 months.

Comparison 4 ASA/DIP versus indobufen, prosthetic grafts, Outcome 4 Primary graft patency, 12 months.
Figures and Tables -
Analysis 4.4

Comparison 4 ASA/DIP versus indobufen, prosthetic grafts, Outcome 4 Primary graft patency, 12 months.

Comparison 5 ASA/DIP versus LMWH, all grafts, Outcome 1 Primary graft patency, 6 months.
Figures and Tables -
Analysis 5.1

Comparison 5 ASA/DIP versus LMWH, all grafts, Outcome 1 Primary graft patency, 6 months.

Comparison 5 ASA/DIP versus LMWH, all grafts, Outcome 2 Primary graft patency, 12 months.
Figures and Tables -
Analysis 5.2

Comparison 5 ASA/DIP versus LMWH, all grafts, Outcome 2 Primary graft patency, 12 months.

Comparison 6 Ticlopidine versus nothing, venous grafts, Outcome 1 Primary graft patency, 1 month.
Figures and Tables -
Analysis 6.1

Comparison 6 Ticlopidine versus nothing, venous grafts, Outcome 1 Primary graft patency, 1 month.

Comparison 6 Ticlopidine versus nothing, venous grafts, Outcome 2 Primary graft patency, 6 months.
Figures and Tables -
Analysis 6.2

Comparison 6 Ticlopidine versus nothing, venous grafts, Outcome 2 Primary graft patency, 6 months.

Comparison 6 Ticlopidine versus nothing, venous grafts, Outcome 3 Primary graft patency, 12 months.
Figures and Tables -
Analysis 6.3

Comparison 6 Ticlopidine versus nothing, venous grafts, Outcome 3 Primary graft patency, 12 months.

Comparison 6 Ticlopidine versus nothing, venous grafts, Outcome 4 Primary graft patency, 24 months.
Figures and Tables -
Analysis 6.4

Comparison 6 Ticlopidine versus nothing, venous grafts, Outcome 4 Primary graft patency, 24 months.

Comparison 7 ASA versus prostaglandin (PGE1), venous grafts, Outcome 1 Early occlusion.
Figures and Tables -
Analysis 7.1

Comparison 7 ASA versus prostaglandin (PGE1), venous grafts, Outcome 1 Early occlusion.

Comparison 8 ASA/DIP versus vitamin K antagonists, all grafts, Outcome 1 Primary graft patency, 3 months.
Figures and Tables -
Analysis 8.1

Comparison 8 ASA/DIP versus vitamin K antagonists, all grafts, Outcome 1 Primary graft patency, 3 months.

Comparison 8 ASA/DIP versus vitamin K antagonists, all grafts, Outcome 2 Primary graft patency, 6 months.
Figures and Tables -
Analysis 8.2

Comparison 8 ASA/DIP versus vitamin K antagonists, all grafts, Outcome 2 Primary graft patency, 6 months.

Comparison 8 ASA/DIP versus vitamin K antagonists, all grafts, Outcome 3 Primary graft patency, 12 months.
Figures and Tables -
Analysis 8.3

Comparison 8 ASA/DIP versus vitamin K antagonists, all grafts, Outcome 3 Primary graft patency, 12 months.

Comparison 8 ASA/DIP versus vitamin K antagonists, all grafts, Outcome 4 Primary graft patency, 24 months.
Figures and Tables -
Analysis 8.4

Comparison 8 ASA/DIP versus vitamin K antagonists, all grafts, Outcome 4 Primary graft patency, 24 months.

Comparison 9 ASA versus naftidrofuryl, Outcome 1 Adverse events.
Figures and Tables -
Analysis 9.1

Comparison 9 ASA versus naftidrofuryl, Outcome 1 Adverse events.

Comparison 9 ASA versus naftidrofuryl, Outcome 2 Reocclusion, 12 months.
Figures and Tables -
Analysis 9.2

Comparison 9 ASA versus naftidrofuryl, Outcome 2 Reocclusion, 12 months.

Comparison 9 ASA versus naftidrofuryl, Outcome 3 Death.
Figures and Tables -
Analysis 9.3

Comparison 9 ASA versus naftidrofuryl, Outcome 3 Death.

Table 1. Patient characteristics

Study ID

% CLI

% below knee

% vein

%1‐vessel run‐off

dose

preoperative start

treatm. duration

randomisation before

ABI preop to postop

Clyne1987

70

85

63

24

ASA 2x300 mg, DIP 2x200 mg

DIP

6 weeks

before

0.38 to 0.78

Donaldson 1985

0

32

0

37

ASA 3x330 mg, DIP 75 mg

1xASA/DIP

12 months

before

0.62 to nd

Goldman 1984

80

47

0

nd

ASA 3 x300 mg, DIP 3x75mg

2 days ASAIDIP

12 months

before

nd

Green 1982

82

47

0

nd

ASA 3 x 325 mg, DIP 3x75mg

2 days ASA/DIP

12 months

before

0.42 to 1.01

Kohler 1984

76

52

69

nd

ASA 3 x 325 mg, DIP 3x 75 mg

first postop day

24 months

before

nd

McCollum 1991

60

59

100

nd; vein<4mm:38

ASA 2x300mg, DIP 2x 150mg

2 days ASA/DIP

continuing indefinitely

before

0.47 to nd

Lucas 1984

55

nd

27

nd

ASA 1050 mg,DIP 150 mg or 1200 mg PTX

preop

6 months

before

0.4

Raithel 1987

95

nd

0

56

ASA 1500 mg vs PTX1200 mg

48 h

12 months

before

nd

d'Addato 1992

70

25

0

56

ASA 900 mg, DIP 225 mg vs 400 mg IND

48 h

12 months

before

nd

BOA 2000

50

52

58.5

nd

ASA 80 mg vs coumarin INR 3.0‐4.5 reached in 50%

within 5 days until 1 month postop

21 months

before

nd

Noppeney 1988

nd

nd

nd

nd

ASA 1500mg vs naftidrofuryl 600 mg daily orally

Day 1 postop

12 months

before

nd

Schneider 1979

nd

nd

100

nd

ASA 1000 mg, DIP225 mg vs coumarin

postoperatively

24 months

postop

nd

Figures and Tables -
Table 1. Patient characteristics
Comparison 1. ASA or ASA/DIP vs nothing, all grafts

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Primary graft patency at 12 months Show forest plot

6

966

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.59 [0.45, 0.79]

2 Amputation rate Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Totals not selected

3 Cardiovascular events Show forest plot

4

811

Odds Ratio (M‐H, Fixed, 95% CI)

0.71 [0.47, 1.08]

4 Gastrointestinal side‐effects Show forest plot

6

966

Odds Ratio (M‐H, Fixed, 95% CI)

1.44 [0.92, 2.24]

5 Death Show forest plot

3

750

Odds Ratio (M‐H, Fixed, 95% CI)

0.82 [0.54, 1.23]

6 Side effects Show forest plot

6

966

Odds Ratio (M‐H, Fixed, 95% CI)

1.55 [1.00, 2.41]

7 Major Bleeding Show forest plot

2

598

Odds Ratio (M‐H, Fixed, 95% CI)

1.88 [0.85, 4.16]

8 Minor bleeding Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Totals not selected

9 Wound or graft infection Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Totals not selected

Figures and Tables -
Comparison 1. ASA or ASA/DIP vs nothing, all grafts
Comparison 2. ASA or ASA/DIP vs nothing, subgroups

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Primary graft patency, venous grafts, 1 month Show forest plot

2

642

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.76 [0.26, 2.24]

2 Primary graft patency, venous grafts, 3 months Show forest plot

2

642

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.85 [0.54, 1.35]

3 Primary graft patency, venous grafts, 6 months Show forest plot

2

642

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.88 [0.59, 1.31]

4 Primary graft patency, venous grafts, 12 months Show forest plot

2

642

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.69 [0.48, 0.99]

5 Primary graft patency, venous grafts, 24 months Show forest plot

2

620

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.72 [0.51, 1.00]

6 Primary graft patency, prosthetic grafts, 1 month Show forest plot

4

222

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.22 [0.10, 0.50]

7 Primary graft patency, prosthetic grafts, 3 months Show forest plot

4

222

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.33 [0.17, 0.68]

8 Primary graft patency, prosthetic grafts, 6 months Show forest plot

4

222

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.23 [0.13, 0.42]

9 Primary graft patency, prosthetic grafts, 12 months Show forest plot

4

222

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.22 [0.12, 0.38]

Figures and Tables -
Comparison 2. ASA or ASA/DIP vs nothing, subgroups
Comparison 3. Aspirin or ASA/DIP versus pentoxifylline (PTX), all grafts

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Primary graft patency, 1 month Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Totals not selected

2 Primary graft patency, 3 months Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Totals not selected

3 Primary graft patency, 6 months Show forest plot

2

151

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.31 [0.56, 3.05]

4 Primary graft patency, 12 months Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Totals not selected

Figures and Tables -
Comparison 3. Aspirin or ASA/DIP versus pentoxifylline (PTX), all grafts
Comparison 4. ASA/DIP versus indobufen, prosthetic grafts

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Primary graft patency, 3 months Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Totals not selected

2 Primary graft patency, 6 months Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Totals not selected

3 Primary graft patency, 9 months Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Totals not selected

4 Primary graft patency, 12 months Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Totals not selected

Figures and Tables -
Comparison 4. ASA/DIP versus indobufen, prosthetic grafts
Comparison 5. ASA/DIP versus LMWH, all grafts

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Primary graft patency, 6 months Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Totals not selected

2 Primary graft patency, 12 months Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Totals not selected

Figures and Tables -
Comparison 5. ASA/DIP versus LMWH, all grafts
Comparison 6. Ticlopidine versus nothing, venous grafts

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Primary graft patency, 1 month Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Totals not selected

2 Primary graft patency, 6 months Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Totals not selected

3 Primary graft patency, 12 months Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Totals not selected

4 Primary graft patency, 24 months Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Totals not selected

Figures and Tables -
Comparison 6. Ticlopidine versus nothing, venous grafts
Comparison 7. ASA versus prostaglandin (PGE1), venous grafts

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Early occlusion Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Totals not selected

Figures and Tables -
Comparison 7. ASA versus prostaglandin (PGE1), venous grafts
Comparison 8. ASA/DIP versus vitamin K antagonists, all grafts

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Primary graft patency, 3 months Show forest plot

2

2741

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.89 [0.69, 1.15]

2 Primary graft patency, 6 months Show forest plot

2

2741

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.99 [0.81, 1.22]

3 Primary graft patency, 12 months Show forest plot

2

2741

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.92 [0.77, 1.11]

4 Primary graft patency, 24 months Show forest plot

2

2741

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.91 [0.77, 1.08]

Figures and Tables -
Comparison 8. ASA/DIP versus vitamin K antagonists, all grafts
Comparison 9. ASA versus naftidrofuryl

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Adverse events Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Totals not selected

1.1 Side effects

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

1.2 Gastrointestinal side effects

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

1.3 Vertigo

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

1.4 Stomach bleeding

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

2 Reocclusion, 12 months Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Totals not selected

3 Death Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Totals not selected

Figures and Tables -
Comparison 9. ASA versus naftidrofuryl